Lazard Asset Management LLC Buys New Position in Myovant Sciences Ltd. (NYSE:MYOV)

Lazard Asset Management LLC bought a new stake in shares of Myovant Sciences Ltd. (NYSE:MYOVGet Rating) during the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor bought 5,643 shares of the company’s stock, valued at approximately $70,000.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Tarbox Family Office Inc. bought a new stake in shares of Myovant Sciences during the 2nd quarter valued at about $342,000. Blueshift Asset Management LLC bought a new stake in shares of Myovant Sciences during the 1st quarter valued at about $293,000. Skandinaviska Enskilda Banken AB publ bought a new stake in shares of Myovant Sciences during the 1st quarter valued at about $48,000. Apis Capital Advisors LLC bought a new stake in shares of Myovant Sciences during the 1st quarter valued at about $533,000. Finally, Arizona State Retirement System bought a new stake in shares of Myovant Sciences during the 1st quarter valued at about $134,000. Institutional investors own 30.62% of the company’s stock.

Myovant Sciences Stock Up 0.1 %

Shares of Myovant Sciences stock opened at $26.85 on Friday. The company has a market cap of $2.60 billion, a PE ratio of -13.43 and a beta of 2.26. Myovant Sciences Ltd. has a 52 week low of $7.67 and a 52 week high of $26.90. The business has a 50 day moving average price of $24.16 and a 200-day moving average price of $17.31.

Myovant Sciences (NYSE:MYOVGet Rating) last issued its quarterly earnings data on Wednesday, October 26th. The company reported ($0.47) EPS for the quarter, topping the consensus estimate of ($0.49) by $0.02. The company had revenue of $104.82 million during the quarter, compared to analysts’ expectations of $92.00 million. As a group, research analysts anticipate that Myovant Sciences Ltd. will post -1.82 EPS for the current year.

Analyst Ratings Changes

A number of research analysts recently weighed in on the company. SVB Leerink downgraded Myovant Sciences from an “outperform” rating to a “market perform” rating and upped their price target for the stock from $23.00 to $27.00 in a research note on Monday, October 24th. StockNews.com assumed coverage on Myovant Sciences in a research note on Wednesday, October 12th. They set a “hold” rating on the stock. Robert W. Baird downgraded Myovant Sciences from an “outperform” rating to a “neutral” rating and upped their price target for the stock from $20.00 to $27.00 in a research note on Monday, October 24th. Finally, The Goldman Sachs Group upped their price target on Myovant Sciences from $9.00 to $10.00 and gave the stock a “neutral” rating in a research note on Thursday, July 28th.

Insider Transactions at Myovant Sciences

In other news, insider Lauren Merendino sold 1,703 shares of the stock in a transaction that occurred on Tuesday, October 18th. The stock was sold at an average price of $25.20, for a total value of $42,915.60. Following the completion of the sale, the insider now directly owns 171,546 shares of the company’s stock, valued at $4,322,959.20. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. In related news, insider Uneek Mehra sold 9,243 shares of the stock in a transaction that occurred on Friday, September 16th. The stock was sold at an average price of $18.86, for a total transaction of $174,322.98. Following the completion of the sale, the insider now directly owns 204,937 shares of the company’s stock, valued at $3,865,111.82. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider Lauren Merendino sold 1,703 shares of the stock in a transaction that occurred on Tuesday, October 18th. The shares were sold at an average price of $25.20, for a total value of $42,915.60. Following the sale, the insider now directly owns 171,546 shares of the company’s stock, valued at $4,322,959.20. The disclosure for this sale can be found here. Insiders sold a total of 19,296 shares of company stock valued at $422,525 over the last ninety days. 1.90% of the stock is currently owned by insiders.

About Myovant Sciences

(Get Rating)

Myovant Sciences Ltd., a biopharmaceutical company, develops redefine care for women and for men. The company's lead product is relugolix, an oral, once-daily, small molecule that acts as a gonadotropin-releasing hormone receptor antagonist for the treatment of heavy menstrual bleeding related with uterine fibroids, endometriosis-associated pain, and advanced prostate cancer.

Featured Stories

Want to see what other hedge funds are holding MYOV? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Myovant Sciences Ltd. (NYSE:MYOVGet Rating).

Institutional Ownership by Quarter for Myovant Sciences (NYSE:MYOV)

Receive News & Ratings for Myovant Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Myovant Sciences and related companies with MarketBeat.com's FREE daily email newsletter.